Epigenetic Biomarkers in Cancer

A cancer biomarker is a biological marker which indicates the presence of cancer in the body. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers are used for diagnosis, prognosis, and epidemiology of cancer.

Because they are expressed against a person's genetic background and environmental exposure, and epigenetic events occur early in cancer development, Epigenetic biomarkers are more advantageous over other types of biomarkers.

Epigenetic biomarkers potentially have numerous clinical applications in cancer intervention and treatment and significant implications for public health.

Types of epigenetic biomarkers:

  • DNA methylation, circulating or noncirculating
  • MicroRNA and other noncoding RNA
  • Protein markers

For e.g., DNA methylation is one of the major epigenetic mechanisms and it is a genetic feature better reflecting disease development and, consequently, has the potential to become a more conclusive biomarker for detection and diagnosis of different diseases.

    Related Conference of Epigenetic Biomarkers in Cancer

    June 10-11, 2024

    8th Global Meeting on Oncology and Radiology

    Barcelona, Spain
    July 11-12, 2024

    24th World Congress on Cancer and Diagnostics

    Vancouver, Canada
    July 18-19, 2024

    14th World Congress on Breast Cancer

    Paris, France
    September 16-17, 2024

    9th World Conference on Breast and Cervical Cancer

    London, UK
    September 19-20, 2024

    25th World Congress on Cancer Summit

    Paris, France
    November 24-25, 2024

    7th International Conference on Anti-Cancer Drugs

    Vancouver, Canada

    Epigenetic Biomarkers in Cancer Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in